

ACMG Annual Clinical Genetics Meeting – *a virtual experience*

April 8 – July 16, 2021

COURSE DESCRIPTION

The 2021 ACMG Annual Clinical Genetics Meeting – a virtual experience presents both research and clinical topics that promote the science and the practice of clinical genetics and genomics. Sessions focus on the latest discoveries of the etiology and the pathogenesis of genetic disorders, the latest developments in genetic testing and screening, the laboratory's role in the diagnosis of genetic disorders, the treatment of genetic disorders in children and adults, the delivery of genetic services, and more.

This course contains accredited simulative sessions with recorded content and live Q&A, ondemand sessions, short courses, scientific sessions, platform sessions, and satellite symposia.

Participants must watch a session, complete an evaluation, and claim credit up to the maximum allowed for a session. This AMA "Other" format is a combination of live and recorded sessions. In late July, ACMG will produce a 2021 Digital Edition that will have quiz questions.

LEARNING OBJECTIVES

At the conclusion of this course, participants should be able to:

- Describe the advances in genetic testing including prenatal and postnatal indications, gene panels, genome sequencing, interpretation, genetic counseling, and ethical and legal issues.
- Review select rare and common genetic disorders, from developmental disabilities to cancer predisposition syndromes, and learn about novel therapeutic approaches including gene editing.
- Review select inborn errors of metabolism, approaches to their diagnoses and treatment, as well as new disorders on the recommended uniform screening panel.
- Discuss challenges of the COVID 19 pandemic and different solutions to deliver the tripartite mission of clinical care, education, and research in medical genetics.
- Describe a potpourri of issues relating to medical genetics including history; ethical, legal and regulatory issues; health disparities, job negotiation; and many others.

TARGET AUDIENCE

All healthcare professionals interested in the diagnosis, management, treatment and prevention of genetic conditions and increasing their understanding of the genetic basis of common, chronic health problems affecting both children and adults will find the programming applicable to their practice. These select sessions from the ACMG Annual Meeting are targeted for the following professionals:

- Medical and clinical geneticists; genetic counselors; pediatric, obstetric, and maternal-fetal specialists; and all medical practitioners who are providing comprehensive diagnostic, management, and counseling services for patients with, or at risk for, genetically influenced health problems
- Laboratory directors and technicians who conduct genetic testing
- Researchers involved in the discovery of genetic disorders and treatments
- Clinical, laboratory and research trainees of genetics and all biomedical sciences
- Any healthcare and public health professionals who have an interest in medical and clinical genetics and genomics
- Advocates for patients with genetic conditions and their families

Continuing Education Information

CME, CCP, P.A.C.E.[®], NSGC Educational Credits

Continuing Medical Education (CME)

Accreditation

The American College of Medical Genetics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this other activity for a maximum of 71.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(total includes Short Course)

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Non-physicians may request a certificate of attendance for their participation.

ABMGG Lifelong Learning and Self-Assessment (CCP Part II)

ABMGG diplomates must demonstrate involvement in continuing education as part of the Lifelong Learning and Self-Assessment (Part II) requirement of the ABMGG Continuing Certification Program (CCP). The ABMGG has approved participation in the short courses offered at the 2021 ACMG Annual Clinical Genetics Meeting as alternative activities for the ABMGG literature review modules. Successful completion of a short course, including participation in the evaluation component, enables the participant to earn a certificate of completion for submission via the ABMGG Portal to fulfill this requirement.

P.A.C.E.[®] CEU's

ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.[®]) Program.

ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). This course is registered with CEBroker # 20-835098. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®. This activity has been approved for 80.5 P.A.C.E.® CEU's. (inclusive of Short Courses)

National Society of Genetic Counselors (NSGC)

The National Society of Genetic Counselors (NSGC) has authorized ACMG to offer up to 8.05 CEUs or 80.50 Category 1 contact hours for the activity ACMG Annual Clinical Genetics Meeting – a virtual experience. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

NSGC Credits must be claimed by July 16, 2021. Credits claimed after this deadline will be reported at the end of December 1, 2021. NSGC Users ID's are required for all participants wishing to claim NSGC CEUs.

All other credits must be claimed by December 1, 2021.

Disclosure Statement

The American College of Medical Genetics and Genomics has implemented a process where everyone who is in a position to influence and/or control the content of a continuing education activity must disclose all relevant financial relationships with any commercial interest within the past 12 months and any conflicts must be resolved prior to the activity. Participants of educational programs must be informed of an organizer's and/or a presenter's academic and professional affiliations and existence of any relevant financial relationship a presenter has with any proprietary entity producing health care goods or services consumed by, or used on patients, with the exemption of non-profit or government organization and non-health care related companies. The intent of this disclosure is not to prevent a speaker from making a presentation. This policy allows the participant to be fully knowledgeable in evaluating the information being presented. All disclosures have been reviewed by the COI sub-committee conflicts of interest are resolved. Disclosure includes any relevant relationship that may potentially bias the planning of the continuing education activity or may potentially bias one's presentation or which, if known, could give the perception of bias.

ACMG Conflict of Interest Policy

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. All educational programming is developed and must be presented in compliance with all ACCME accreditation requirements.

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American College of Medical Genetics and Genomics must insure balance, independence, objectivity, and scientific rigor in all educational activities. Planning must be free of the influence or control of a commercial entity, and promote improvements or quality in healthcare. All scientific research used to support patient care recommendations must conform to generally accepted standards of experimental design, data collection, and analysis. In accordance with the ACCME Standards for Commercial Support, everyone (speakers, moderators, oral abstract presenters, all authors, committee members, and staff) who are in a position to control the content of an educational activity certified for *AMA PRA Category 1 Credit™* must disclose all relevant financial relationships with any commercial interests within the past 12 months.

Individuals who do not disclose are disqualified from participating in a CME activity. Should the speaker's presentation include discussion of any off-labeled/investigational use of a commercial product, he/she is also required to disclose this to the activity participants.

Conflict of interest is created when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The potential for maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME—an incentive to insert commercial bias. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g. stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.

A **Commercial interest** is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Diagnostic Laboratories

A diagnostic laboratory is not considered an ACCME-defined commercial interest if its business is limited to the provision of diagnostic services that provide clinical results or information to healthcare professionals for their treatment of patients.

A diagnostic laboratory is considered an ACCME-defined commercial interest if it produces, markets, distributes, or re-sells proprietary diagnostic products or devices to other entities or individuals, such as other laboratories, clinics, clinicians, or patients for the provision of clinical service—for example, providing on-site or in-home clinical results.

A diagnostic laboratory that is owned or controlled by an ACCME-defined commercial interest is considered an ACCME-defined commercial interest.

Relevant financial relationships as defined by the ACCME requires anyone in control of CME content to disclose relevant financial relationships to the accredited provider. Individuals must also include in their disclosure the relevant financial relationships of a spouse or partner.

Content Validation and Fair Balance

1. ACMG follows the ACCME policy on Content Validation for CME activities, which requires:

a) All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.

b) All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.

2. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.

3. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-label Uses of Products

When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.

HIPAA Compliance by Faculty

The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to at that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available upon request.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and s or exclusive of other procedures and s that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or , a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net

Session Title All times listed in Eastern US Time Zone Schedule Subject to Change Posted 3/11/2021	Session Type	CME	P.A.C.E.®	NSGC	Date	Start Time	End Time
Laboratory Diagnostic Challenges (Constitutional and Neoplastic Cases in Molecular, Cytogenomic, and Biochemical Genetics Specialties)	Scientific Plenary Session	2	2	2	4/8/2021	3:00 PM	5:00 PM
Plain People, Precision Medicine, and the Legacy of Victor McKusick	Online Exclusive	1.5	1.5	1.5	4/13/2021	8:00 AM	
Power in Numbers: The Benefits of Rare Disease Consortia in Inborn Errors of Metabolism	Online Exclusive	1.5	1.5	1.5	4/13/2021	8:00 AM	

Session Title All times listed in Eastern US Time Zone Schedule Subject to Change Posted 3/11/2021								
	Session Type	CME	P.A.C.E.®	NSGC	Date	Start Time	End Time	
Looking Beyond the Lamppost: Genome-First Approaches to Disease Prevalence, Penetrance, and Phenotype	Online Exclusive	1.5	1.5	1.5	4/13/2021	8:00 AM		
The Evolution of Autopsy in the Era of Sequencing	Online Exclusive	1.5	1.5	1.5	4/13/2021	8:00 AM		
Clinical, Legal, Ethical, and Economic Issues Surrounding Variant Reinterpretation	Online Exclusive	1.5	1.5	1.5	4/13/2021	8:00 AM		
Diversity in Clinical Genetics Practices Around the World	Online Exclusive	1.5	1.5	1.5	4/13/2021	8:00 AM		
A Clinician's Perspective on Obesity: Syndromic and Non-Syndromic Causes, Treatment and Challenges	Short Course**	4.5	4.5	4.5	4/13/2021	12:00 PM	5:00 PM	
Integration of Functional Genomics to Improve Variant Interpretation and Diagnosis	Short Course**	4.5	4.5	4.5	4/13/2021	12:00 PM	5:00 PM	
Early Career Job Hunt and Transition Success - What We Wish We had Known	Trainee Workshop	n/a	n/a	n/a	4/13/2021	5:30 PM	7:00 PM	
Genomic Informatics on Clinical Service and Approaches to Evaluate the Unknown/Uncertain	Workshop	1.5	1.5	1.5	4/13/2021	5:30 PM	7:00 PM	
Long-Chain Fatty Acid Oxidation Disorders: Emerging Developments (<i>This activity is sponsored by Excel Continuing Education and supported by an educational grant from Ultragenyx Pharmaceuticals</i>)	Satellite Symposium	*	1.5	1.5	4/14/2021	8:00 AM	9:30 AM	
Cases and Conversations: Optimizing Patient-Centric Care for Chronic Acid Sphingomyelinase Deficiency: From Early Diagnosis to Emerging (<i>This activity is sponsored by Physician's Education Resource and supported by an educational grant from Sanofi Genzyme</i>)	Satellite Symposium	*	1.5	1.5	4/14/2021	8:00 AM	9:30 AM	
Cases and Conversations: Exploring the Implications of Variants of Unknown Significance (VUS) in Fabry Disease (<i>This activity is sponsored by Physician's Education Resource and supported by an educational grant from Amicus Therapeutics</i>)	Satellite Symposium	*	1.5	1.5	4/14/2021	8:00 AM	9:30 AM	
ACMG Presidential Plenary Session: Keeping Vulnerable People Safe During the COVID19 Pandemic	Scientific Plenary Session	n/a	n/a	n/a	4/14/2021	10:00 AM	11:30 AM	
Industry Platform Presentations 1 (Educational credits are not available)	Platform	n/a	n/a	n/a	4/14/2021	12:00 PM	1:00 PM	
Chromatinopathies: An Expanding Clinical Spectrum	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	1:00 PM	2:30 PM	
The Heart of the Matter - Congenital Cardiac Disease and Pregnancy	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	1:00 PM	2:30 PM	

Session Title All times listed in Eastern US Time Zone Schedule Subject to Change Posted 3/11/2021								
	Session Type	CME	P.A.C.E.®	NSGC	Date	Start Time	End Time	
Heritable Human Genome Editing in Clinical Practice: Scientific, Social, Ethical, and Legal Perspectives	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	1:00 PM	2:30 PM	
Adult and Cancer Diagnostic Challenges	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	1:00 PM	2:30 PM	
Excellence in Medical Genetics and Genomics Through Diversity	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	3:30 PM	5:00 PM	
Telegenetics: Before, During and After COVID-19	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	3:30 PM	5:00 PM	
Gene-Based Medicines to Treat Metabolic Disorders: Progress and Perspectives	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	3:30 PM	5:00 PM	
Hot Topics: Pushing the Boundaries of Genome Sequencing	Scientific Concurrent Session	1.5	1.5	1.5	4/14/2021	3:30 PM	5:00 PM	
Platform Presentations- Cancer Genetics and Therapeutics	Platform	1.5	1.5	1.5	4/14/2021	5:30 PM	7:00 PM	
Platform Presentations -Genetic Counseling	Platform	1.5	1.5	1.5	4/14/2021	5:30 PM	7:00 PM	
Platform Presentations- Legal and Ethical Issues; Education	Platform	1.5	1.5	1.5	4/14/2021	5:30 PM	7:00 PM	
Platform Presentations- Clinical Genetics and Therapeutics	Platform	1.5	1.5	1.5	4/14/2021	5:30 PM	7:00 PM	
The Future of Pediatric Rare Disease Diagnosis is NOW: Update on Genomic Sequencing in Acutely Ill Infants and Pediatric Outpatients <i>(This activity is sponsored by EXCEL Continuing Education and supported by an educational grant from Illumina)</i>	Satellite Symposium	*	1.5	1.5	4/15/2021	8:00 AM	9:30 AM	
Metabolic Mysteries: Puzzling Patient Cases with Metabolic Implications <i>(This activity is sponsored by EXCEL Continuing Education and supported by an educational grant from Recordati Rare Diseases)</i>	Satellite Symposium	*	1.5	1.5	4/15/2021	8:00 AM	9:30 AM	
Cases and Conversations: The Importance of Newborn Screening for MPS1 – How Can We Optimize Patient Outcomes from The Beginning? <i>(This activity is sponsored by Physicians' Education Resource LLC and supported by an educational grant from Sanofi Genzyme)</i>	Satellite Symposium	*	1.5	1.5	4/15/2021	8:00 AM	9:30 AM	
Featured Platform Presentations	Platform	1	1	1	4/15/2021	10:00 AM	11:00 AM	

Session Title All times listed in Eastern US Time Zone Schedule Subject to Change Posted 3/11/2021								
	Session Type	CME	P.A.C.E.®	NSGC	Date	Start Time	End Time	
TED-Style Talks with Steve Cole and Janina Jeff	Scientific Plenary Session	n/a	n/a	n/a	4/15/2021	11:00 AM	12:00 PM	
Genetic Counselor Forum: In Utero Fetal Molecular Therapies: Present State and Future Applications	Genetic Counselor Forum	1	1	1	4/15/2021	12:00 PM	1:00 PM	
Pediatric Tumor Predisposition Syndromes: Update on Clinical Phenotypes, Associated Tumors, and Clinical Approaches to Surveillance	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	1:00 PM	2:30 PM	
RNA and Gene Therapy in the Clinic – From Discovery to Treatment Implementation	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	1:00 PM	2:30 PM	
Implementation of Whole Genome Sequencing as an Example of How to Bridge the Divide Between Research and Clinical Practice	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	1:00 PM	2:30 PM	
Prenatal Diagnostic Challenges	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	1:00 PM	2:30 PM	
Sex Chromosome Trisomies - To Screen or Not to Screen? - That is the Question	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	3:30 PM	5:00 PM	
Bringing the New Era of Mitochondrial Genomic Medicine to Geneticists	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	3:30 PM	5:00 PM	
Unexpected Findings Across the Lifespan: Challenges of Reporting Incidental and Secondary Findings in Young Patients	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	3:30 PM	5:00 PM	
A Primer on Regulatory and Compliance Agencies in Genetic Testing	Scientific Concurrent Session	1.5	1.5	1.5	4/15/2021	3:30 PM	5:00 PM	
Platform Presentations- Public Health, Health Services and Implementation	Platform	1.5	1.5	1.5	4/15/2021	5:30 PM	7:00 PM	
Platform Presentations- Prenatal Genetics	Platform	1.5	1.5	1.5	4/15/2021	5:30 PM	7:00 PM	
Platform Presentations- Biochemical/Metabolic Genetics	Platform	1.5	1.5	1.5	4/15/2021	5:30 PM	7:00 PM	
Platform Presentations- Laboratory Genetics and Genomics	Platform	1.5	1.5	1.5	4/15/2021	5:30 PM	7:00 PM	
Navigating Treatment Access Challenges in IEMs, Including UCDs: A Case-Based Discussion <i>(This activity is sponsored by Horizon Therapeutics)</i>	Satellite Symposium	n/a	n/a	n/a	4/16/2021	8:00 AM	9:00 AM	
Fabry Disease in the Era of COVID-19: Implications for Clinical Practice <i>(This activity is sponsored by Chiesi USA, Inc.)</i>	Satellite Symposium	n/a	n/a	n/a	4/16/2021	8:00 AM	9:30 AM	
Bardet Biedl Syndrome: Genetic Pathophysiology and Clinical Characteristics	Satellite Symposium	n/a	n/a	n/a	4/16/2021	8:00 AM	9:30 AM	

Session Title All times listed in Eastern US Time Zone Schedule Subject to Change Posted 3/11/2021							
	Session Type	CME	P.A.C.E. ®	NSGC	Date	Start Time	End Time
(This activity is sponsored by Rhythm Pharmaceuticals, Inc.)							
Clinical Insights from SMART, the Largest Prospective NIPT Study: Innovation with SNP-based NIPT (This activity is sponsored by Natera)	Satellite Symposium	n/a	n/a	n/a	4/16/2021	8:00 AM	9:00 AM
Artificial Intelligence and Genomics – Powerful Tools in Pre- and Postnatal Decision Making	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	10:00 AM	11:30 AM
The Ehlers-Danlos Syndromes, Circa 2021: Clinical and Molecular Updates	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	10:00 AM	11:30 AM
What’s in a Panel? A Decade of Expanded Carrier Screening in Review	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	10:00 AM	11:30 AM
Industry Platform Presentations 2 (Educational credits are not available)	Platform	n/a	n/a	n/a	4/16/2021	12:30 PM	1:30 PM
The Intersection Between Developmental Phenotypes and Perinatal Genomic Diagnoses	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	1:00 PM	2:30 PM
Clinical Pharmacogenomic Testing: Current Best Practices and Future Landscape	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	1:00 PM	2:30 PM
Genetic Health Disparities: From Biology to Healthcare Delivery Systems	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	1:00 PM	2:30 PM
ACMG 2021 Cardinal Signs	Scientific Concurrent Session	1.5	1.5	1.5	4/16/2021	1:00 PM	2:30 PM
R. Rodney Howell Symposium Genetics in Medicine Presents: Spring 2021 COVID-19 State of the Science	Scientific Plenary Session	1.5	1.5	1.5	4/16/2021	3:00 PM	4:45 PM
Total Possible Credits		71.5	80.5	80.5			
*Other ACCME Accredited ** CCP Part II credit applies							

Financial Disclosures

Disclosure Statement

The American College of Medical Genetics and Genomics has implemented a process where everyone who is in a position to influence and/or control the content of a continuing education activity must disclose all relevant financial relationships with any commercial interest within the past 12 months and any conflicts must be resolved prior to the activity. Participants of educational programs must be informed of an organizer's and/or a presenter's academic and professional affiliations and existence of any relevant financial relationship a presenter has with any proprietary entity producing health care goods or services consumed by, or used on patients, with the exemption of non-profit or government organization and non-health care

related companies. The intent of this disclosure is not to prevent a speaker from making a presentation. This policy allows the participant to be fully knowledgeable in evaluating the information being presented. All disclosures have been reviewed by the COI sub-committee conflicts of interest are resolved. Disclosure includes any relevant relationship that may potentially bias the planning of the continuing education activity or may potentially bias one's presentation or which, if known, could give the perception of bias.

Financial Disclosures

Members of the ACMG Program Committee have the following disclosures:

- Sarah Elsea, PhD, FACMG – Research Grants with NIH, PRISMS, Inc., Shire Genetic Therapies, Rhythm Therapeutics, Jerome Lejeune Foundation; Consultant with Enzyvant and Speragen, Member of ACMG Foundation Board
- Akash Kumar, MD, PhD (Trainee), Major Stockholder in MyOme, Inc.
- David Stevenson, MD, FACMG, Research Grant with Soleno clinical trial, Consultant with GLG and BMJ Publisher, Member of Costello support group, CFC support group, and PWSA Support Group

The following members have nothing to disclose:

- Jennelle C. Hodge, PhD, FACMG (Co-Chair)
- Tuya Pal, MD, FACMG (Co-Chair)
- Myra Wick, MD, PhD, FACMG (Vice Chair)
- Anthony Gregg, MD, MBA, FACOG, FACMG (President)
- Kristina Cusmano-Ozog, MD, FACMG
- Keith Eddleman, MD, FACMG
- Michael Gambello, MD, FACMG
- Gerard Berry, MD, FACMG (SIMD Liaison)
- Jodi D. Hoffman, MD, FACMG
- Jennifer King, MD, MS (Candidate Fellow)
- Kelsey McIntyre, PhD, FACMG
- Wendy Rubinstein, MD, FACMG
- Anne Slavotinek, PhD, FACMG (Education Committee Liaison)
- Jessica Smith, MD, FACMG
- Eli Williams, PhD, FACMG
- Samantha Stover, MS, CGC
- Max Muenke, MD, FACMG (Chief Executive Officer)
- Jane Dahlroth, CEM, CMP-HC (Senior Director Meetings & Exhibits)
- Jane Radford, MHA, CHCP (Director of Education)
- Penelope Freire, CMP (Associate Director, Meetings & Exhibits)
- Claudia Barnett (Senior Education Program Coordinator)
- Jenna Cohen, CMP (Manager, Meetings & Exhibits)

SPEAKERS AND MODERATORS DISCLOSURES

Presenters and moderators have disclosed the following:

[Last name, First Name, Degree(s)]

Abul-Husn, Noura, MD, PhD, MS, FACMG

Previously employed relationship with Regeneron Pharmaceuticals; Speaker/Speaker's Bureau relationship with Genentech

Adashi, Eli, MD, MS	Consultant relationship with Ohana Biosciences
Ammous, Zeinab, MD	Consultant relationship with Traverre Therapeutics; Consultant relationship with CoA Therapeutics
Andrews Ashley, MSN, CPNP	Speaker/Speaker's Bureau relationship with Horizon
Berry, Susan, MD	DSMB Member relationship with Sanofi; Clinical Trial Site PI relationship with Hemoshear; Clinical Trial Site PI relationship with Arturus
Bick, David, MD	Consultant relationship with Northwestern Mutual Life Insurance Company; Consultant relationship with iRepertoire Molecular Laboratory
Biffi, Alessandra, MD	research funding, patent and royalty's relationship with Orchard Therapeutics; research funding relationship with Altheia Science
Brigatti, Karlla, MS	Advisory Committee Member relationship with Novartis Gene Therapies
Burghes, Arthur, PhD	Consultant relationship with Novartis Gene Therapy
Burton, Barbara, MD	Consultant relationship with Biomarin; Speaker relationship with Shire; Consultant relationship with Denali; Consultant relationship with Horizon Pharma; Consultant relationship with Ultragenyx; Consultant relationship with Moderna; Consultant relationship with Aeglea
Chapman, Kimberly, MD, PhD	PI on clinical trial relationship with HemoShear Therapeutics
Cherqui, Stephanie, PhD	Owner/Founder relationship with Stelios Therapeutics Inc; Consultant relationship with AVROBIO
Chung, Wendy, MD, PhD	Scientific Medical Advisor relationship with Regeneron Genetic Center; Speaker/Speaker's Bureau relationship with Rhythm
Cunniff, Christopher, MD	Consultant relationship with Sterigenics; Advisory Committee Member relationship with Biogen; Advisory Committee Member relationship with Amgen
Daly, Mark, PhD	Owner/Founder relationship with MAZE Therapeutics
Dhar, Shweta, MD	Owner/Founder relationship with PanGenomics India
Dimmock, David, MD	Advisory Committee Member relationship with Biomarin; Advisory Committee Member relationship with Audentes; Advisory Committee Member relationship with Complete Genomics
Flannery, David, MD	Stockholder relationship with Salus Telehealth
Francomano, Clair, MD	Scientific Medical Advisor relationship with Kyani International; Consultant relationship with Acer Therapeutics
Ganesh, Jaya, MD	Advisory Committee Member relationship with Sangamo; Advisory Committee Member relationship with amicus; Speaker/Speaker's Bureau relationship with chiesi
Gillingham, Melanie, PhD	Patents/Royalties relationship with Ultragenyx; Consultant relationship with Reneo; Speaker/Speaker's Bureau relationship with Vitaflo; Speaker/Speaker's Bureau relationship with Rockpointe CME; Speaker/Speaker's Bureau relationship with Total CME

Gregg, Anthony, MD, MBA, FACOG, FACMG	Consultant relationship with I do participate in medical legal consulting - defense
Hajirasouliha, Iman, PhD	Owner/Founder relationship with STORK AI
Hakim, Alan, MB MA	Consultant relationship with The Ehlers-Danlos Society
Harding, Cary, MD	Scientific Medical Advisor relationship with BioMarin Pharmaceutical Corp.; Research Funding relationship with Ultragenyx Pharmaceutical; Scientific Medical Advisor relationship with Sanofi/Genzyme; Scientific Medical Advisor relationship with Synlogic, Inc.
Haywood, Trent, MD	Founder, Knowality LLC
Hirschhorn, Joel, MD/PhD	Advisory Committee Member relationship with Camp4 THERapeutics
Hollander, Suzanne, MS, RD	Consultant relationship with Horizon
Hopkin, Robert, MD	Scientific Medical Advisor relationship with Sanofi Genzyme; Consultant relationship with Amicus therapeutics; Research Funding relationship with Sangamo; Research Funding relationship with Protalix; Consultant relationship with AvroBio; Consultant relationship with Chiesi
Kamihara, Junne, MD, PhD	Owner/Founder relationship with Rome therapeutics; Owner/Founder relationship with PanTher Therapeutics; Owner/Founder relationship with TellBio, Inc.; Consultant relationship with Rome Therapeutics; Consultant relationship with Pfizer; Consultant relationship with Foundation Medicine, Inc.; Research Funding relationship with ACD-Biotechne; Research Funding relationship with PureTech; Research Funding relationship with Ribon Therapeutics; Speaker/Speaker's Bureau relationship with NanoString Technologies; Consultant relationship with Third Rock Ventures; Consultant relationship with EMD Millipore Sigma
Karaa, Amel, MD	Consultant relationship with Stealth biotherapeutics; Research Funding relationship with Sanofi Genzyme; Research Funding relationship with Takeda; Research Funding relationship with Protalix; Research Funding relationship with Idorsia; Research Funding relationship with Impeto
Karczewski, Konrad, PhD	Consultant relationship with Vor Biopharma; Speaker/Speaker's Bureau relationship with Pfizer; Speaker/Speaker's Bureau relationship with Genentech
Kuhn, Robert, PhD	Patents/Royalties relationship with UCSC Genome Browser authors
Lachmann, Robin, MD, PhD	Consultant relationship with SanofiGenzyme; Speaker/Speaker's Bureau relationship with SanofiGenzyme
Laney, Dawn, MS	Advisory Committee Member relationship with Sanofi-Genzyme; Research Funding relationship with Sanofi-Genzyme; Research Funding relationship with Amicus; Owner/Founder relationship with ThinkGenetic
Larson, Austin, MD	Speaker/Speaker's Bureau relationship with Illumina; Research Funding relationship with Traverre; Research Funding

Lianoglou, Billie, LCGC	relationship with Mallinckrodt; Research Funding relationship with Stealth Biotherapeutics; Advisory Committee Member relationship with Zogenix; Research Funding relationship with Entrada; Research Funding relationship with Neurocrine
Lin, Angela, MD, FACMG	Employee relationship with Denali Therapeutics
Luedecke, Amanda, MS	Consultant relationship with Massachusetts Department Public Health
McCandless, Shawn, MD	Consultant relationship with MyGeneCounsel
	Consultant relationship with LogicBio; Research Funding relationship with Recordati; Consultant relationship with Horizon Therapeutics; Consultant relationship with Levo Therapeutics; Research Funding relationship with Levo Therapeutics
Malhotra, Sonali, MBBS	Speaker/Speaker's Bureau relationship with Rhythm; Consultant relationship with Rubicon MD
Martin, Kimberly, MD	Consultant relationship with Natera
McBride, Kim, MD	Research Funding relationship with Biomarin; Research Funding relationship with Abeona; Research Funding relationship with Homology
Murray, Michael, MD	Scientific Medical Advisor relationship with 54gene
Parikh, Sumit, MD	Employee relationship with Cleveland Clinic; Scientific Medical Advisor relationship with CHAMP Foundation; Research Funding relationship with Astellas; Scientific Medical Advisor relationship with UMDF; Research Funding relationship with Acadia; Research Funding relationship with Minovia
Parmar, Sheetal MS	Employee relationship with Natera
Pratt, Victoria, PhD	Advisory Committee Member relationship with Avalon Healthcare, LLC
Anjay Rastogi, MD, PhD	Speaker bureau for: Amgen, Astrazeneca, Aurinia, Baxter, Fresenius Medical Care, Genzyme/Sanofi, Janssen, Otsuka, Relypsa, Tricida, Natera, Spire Learning. Advisory Board/Consultant: Akebia Ardelyx, Astrazeneca, Aurinia, Fresenius Medical Care-Vifor, GlaxoSmithKline, Otsuka, Vifor Pharma, Sanofi, Ghiesi Global Inc. Research Support for: Alnylam Pharmaceuticals, Bayer, Gilead, GlaxoSmithKline, Idorsia Pharmaceuticals, Kadmon Corp, NIH, Novo Nordisk, Omeros Inc, Pfizer, Protalix Biotherapeutics Reata Pharmaceuticals, Summit Oxford
Robinson, Peter, MD, PhD	Patents/Royalties relationship with The Jackson Laboratory
Schuchman, Edward, PhD	Patents/Royalties relationship with Sanofi-Genzyme; Consultant relationship with Sanofi-Genzyme; Research Funding relationship with Sanofi-Genzyme
Scott, Stuart, PhD	Consultant relationship with Sema4
Simpson, Joe Leigh, MD	Advisory Committee Member relationship with Illumina
Steiner, Robert, MD	Employee relationship with PreventionGenetics; stock and consultant relationship with Acer Therapeutics

Stewart, Douglas, MD	Consultant relationship with Genome Medical, Inc
Sutton, V. Reid, MD	Laboratory Director, Salary Support relationship with Baylor Genetics
Van den Veyver, Ignatia, MD, FACMG	Reagents to support NIH-funded project relationship with Illumina, SAB member, no financial compensation relationship with Baylor Genetics
Venditti, Charles, MD/PhD	Research Funding relationship with Moderna; Research Funding relationship with LogicBio; Research Funding relationship with AskBio; Research Funding relationship with Translate Bio
Vora, Neeta, MD, FACMG	Research Funding relationship with Illumina
Wasserstein, Melissa, MD	Consultant relationship with Sanofi Genzyme; Consultant relationship with Sanofi Genzyme; Research Funding relationship with Sanofi-Genzyme; Consultant relationship with Takeda; Research Funding relationship with Ara Parseghian Medical Research Fund; Research Funding relationship with BioMarin; Research Funding relationship with Cure Sanfilippo Foundation; Research Funding relationship with Dana's Angels Research Trust; Research Funding relationship with Firefly Fund; Research Funding relationship with Orchard Therapeutics; Research Funding relationship with PassageBio; Research Funding relationship with Traverre Therapeutics; Research Funding relationship with Ultragenyx
Weitzel, Jeffrey, MD	Speaker/Speaker's Bureau relationship with AstraZeneca
Williamson Dean, Lori, MS	Advisory Committee Member relationship with GeneDx
Yu, Timothy, MD, PhD	Scientific Medical Advisor relationship with GeneTx Therapeutics; Scientific Medical Advisor relationship with Eisai G2D2; Scientific Medical Advisor relationship with Alnylam
Zori, Robert, MD	Consultant relationship with horizon; Research Funding relationship with biomarin

The following moderators and presenters have nothing to disclose:

[Last name, First Name, Degree(s)]

Abu-El-Haija, Aya, MD MPH	Bird, Lynne, MD	Cutting, Garry, MD
Akbar, Fizza, MS	Bowling, Kevin, PhD	Davis, Erica, PhD
Akkari, Yasmine, PhD	Bradley, David, MD	Dobin, Sheila, PhD
Alkuraya, Fowzan, MD, FACMG	Buchanan, Adam, MS	Dow, Margaret, MD
Appelbaum, Paul, MD	Carey, David, PhD	Ebbert, Mark, PhD
Bailey, Diana, MS	Casanova, Jean-Laurent, MD, PhD	Edmondson, Andrew, MD/PhD
Berg, Jonathan, MD/PhD	Chanprasert, Sirisak, MD	Elias, Ellen, MD
Berry, Gerard, MD	Chung, Brian Hon-Yin, MS, MD	Elsea, Sarah, PhD, FACMG
Bielas, Stephanie, PhD	Clayton, Ellen, MD, JD	Emrick, Lisa, MD
Bien-Willner, Gabriel, PhD, MD	Cusmano-Ozog, Kristina, MD	Eno, Celeste, PhD

Erwin, Angelika, MD, PhD	Langlois, Sylvie, MD	Rotberg, Seth, MS
Evans, Rebecca, CGC	Laukaitis, Christina, MD, PhD	Russell, Bianca, MD
Fahrner, Jill, MD/PhD	Leung, Marco, PhD, FACMG	Sadikovic, Bekim, PhD
Farooqi, Sadaf, PhD, FRCP, FMedSci	McGovern, Margaret, MD, PhD	Samango-Sprouse, Carole, EdD
Fullerton, Stephanie, PhD	Marshall, Christian, PhD	Schaaf, Christian, MD, PhD
Gavrilova, Ralitza, MD	Martin, Christa, PhD	Scheuner, Maren, MD, MS
Geddes, Gabrielle, MD	Martinez-Agosto, Julian, MD. PhD	Scott, Richard, MD, PhD
Giordano, Jessica, MS	Matthews, Andrea, BS	Seaver, Laurie, MD
Glinton, Kevin, MD/PhD	McClure, Michelle, PhD	Shaffer, Brian, MD, FACOG, FACMG
Goldstein, Alisa, PhD	Michael, Drew, PhD, FACMG	Shashi, Vandana, MD
Goldstein, Amy, MD	Might, Matthew, PhD	Shieh, Joseph, MD/PhD
Gray, Kathryn, MD/PhD	Miller, Jennifer, MD	Shinawi, Marwan, MD
Grochowsky, Angela, MD	Miller, Kristen Leppert, MGC, CGC	Slavotinek, Anne, MD, PhD
Gropman, Andrea, MD	Moon-Grady, Anita, MD	Slutsky, Emily, MD, MS
Gupta, Punita, MD	Morava-Kozicz, Eva, MD, PhD	Smith, Jessica, MD, FACMG, FACOG
Haldeman-Englert, Chad, MD	Morgan, Thomas, MD	Soler-Alfonso, Claudia, MD
Hisama, Fuki, MD	Muthusamy, Karthik, MD	Stover, Samantha, CGC
Hodge, Jennelle, PhD	Nelson, Stanley, MD	Suskin, Barrie, MD
Hoening, Megan MS	Ngongang, Cedrik, MD	Sutherland, Nykole, MS
Hurst, Anna, MD, MS, FACMG	Niu, Zhiyv (Neal, PhD, FACMG	Sweeney, Nathaly, MD, MPH, MS
Jensik, Philip, PhD	Oglesbee, Devin, PhD	Tan, Khoon Ghee Queenie, MD, PhD
Ji, Yuan, MS, PhD	Pagan, Jose, PhD	Tan, Wen-Hann, MD
Jobanputra, Vaidehi, PhD	Pal, Tuya, MD	Tatton-Brown, Katrina, MD
Jones, Marilyn, MD	Pekarek, Dawn, MD	Terraf, Panieh, MSc, PhD
Kahn, Jeffrey, PhD, MPH	Perales Clemente, Ester, PhD	Tucci, Arianna, MD PhD
Kashmola-Perez, Iman, MS, LGC	Pina-Aguilar, Raul, PhD, MD	Vockley, Jerry, MD/PhD
Keppler-Noreuil, Kim, MD, FACMG	Popejoy, Alice, PhD	Walton, Nephi, MD, MS
Khalek, Nahla, MD, MPH	Prakash, Siddharth, MD/PhD	Wapner, Ronald, MD
King, Jennifer, MD	Puffenberger, Erik, PhD	Weck, Karen, MD, FCAP
Kirmani, Salman, MBBS, FACMG	Quintero-Rivera, Fabiola, MD	Weksberg, Rosanna, MD/PhD
Klein, Christopher, MD	Rahm, Alanna, PhD, LGC	Williams, Eli, PhD
Koenig, Barbara, PhD	Raraigh, Karen MS	Wolff, Daynna, PhD
Krawitz, Peter, MD, PhD	Rasmussen, Sonja, MD, MS, FACMG	Yang, Chen, MD/PhD
Kraybill, Donald, PhD	Rehm, Heidi, PhD, FACMG	Yap, Kai Lee, PhD
Kronn, David, MD	Roberts, Jessica, JD	
	Rose, Sherrill, MD	

7101 Wisconsin Avenue, Suite 1101 | Bethesda, MD 20814

Telephone: 301-718-9603 | Fax: 301-718-9604 | E-mail: education@acmg.net | Website:

www.acmgmeeting.net

© 2001-2021 American College of Medical Genetics and Genomics All rights reserved.